Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Biomatrix and Orsiro Drug Eluting Stent

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. General Inclusion Criteria~   1. Subject must be at least 18 years of age.~  2. Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving the Biomatrix flex stents or Orsiro stents, and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.~  3. Subject must have significant lesion (\>50% by visual estimate) in any of the coronary arteries, venous or arterial bypass grafts.~  4. Subject must have evidence of myocardial ischemia (e.g., stable, unstable angina, recent infarction, silent ischemia, positive functional study or a reversible changes in the electrocardiogram (ECG) consistent with ischemia). In subjects with diameter stenosis \> 70%, evidence of myocardial ischemia does not have to be documented.~2. Angiographic Inclusion Criteria~   1. Target lesion(s) must be located in coronary artery, venous or arterial bypass graft with diameter of ≥ 2.5 mm and ≤ 4.5 mm.~  2. Target lesion(s) must be amenable for percutaneous coronary intervention.~Exclusion Criteria:~1. The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Cilostazol, Prasugrel, Ticagrelor, Biolimus, Sirolimus, Contrast media (Patients with documented sensitivity to contrast media which can be effectively premedicated with steroids and diphenhydramine \[e.g. rash\] may be enrolled. Those with true anaphylaxis to prior contrast media, however, should not be enrolled.)~2. Systemic (intravenous) Biolimus or Sirolimus use within 12 months.~3. Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study.~4. History of bleeding diathesis, known coagulopathy (including heparin- induced thrombocytopenia), abnormal hemogram (Hb\<10g/dL or PLT count \<100,000/μL) or will refuse blood transfusions~5. Patients with severe LV systolic dysfunction (LVEF\<25%) or cardiogenic shock~6. Gastrointestinal or genitourinary bleeding within the prior 2 months, or major surgery within 2 months.~7. Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment).~8. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow- up period.~9. Symptomatic heart failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Orsiro drug eluting stent (Type: EXPERIMENTAL): Orsiro drug eluting stent
- Biomatrix drug eluting stent (Type: ACTIVE_COMPARATOR): Biomatrix drug eluting stent

Based on this trial design, predict the completion outcome and termination type (if applicable).